Jin Honglin, Qian Yuan, Dai Yanfeng, Qiao Sha, Huang Chuan, Lu Lisen, Luo Qingming, Chen Jing, Zhang Zhihong
Britton Chance Center for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology, Wuhan 430074, China;; MoE Key Laboratory for Biomedical Photonics, Department of Biomedical Engineering, Huazhong University of Science and Technology, Wuhan 430074, China;; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 JieFang Avenue, Wuhan 430022, China.
Britton Chance Center for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology, Wuhan 430074, China;; MoE Key Laboratory for Biomedical Photonics, Department of Biomedical Engineering, Huazhong University of Science and Technology, Wuhan 430074, China.
Theranostics. 2016 Sep 2;6(11):2000-2014. doi: 10.7150/thno.15102. eCollection 2016.
Dendritic cell (DC) migration to the lymph node is a key component of DC-based immunotherapy. However, the DC homing rate to the lymphoid tissues is poor, thus hindering the DC-mediated activation of antigen-specific T cells. Here, we developed a system using fluorescent magnetic nanoparticles (α-AP-fmNPs; loaded with antigen peptide, iron oxide nanoparticles, and indocyanine green) in combination with magnetic pull force (MPF) to successfully manipulate DC migration and . α-AP-fmNPs endowed DCs with MPF-responsiveness, antigen presentation, and simultaneous optical and magnetic resonance imaging detectability. We showed for the first time that α-AP-fmNP-loaded DCs were sensitive to MPF, and their migration efficiency could be dramatically improved both and through MPF treatment. Due to the enhanced migration of DCs, MPF treatment significantly augmented antitumor efficacy of the nanoparticle-loaded DCs. Therefore, we have developed a biocompatible approach with which to improve the homing efficiency of DCs and subsequent anti-tumor efficacy, and track their migration by multi-modality imaging, with great potential applications for DC-based cancer immunotherapy.
Int J Nanomedicine. 2013-10-7
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013-4-30
Microorganisms. 2025-2-18
Nanomaterials (Basel). 2025-1-16
Front Bioeng Biotechnol. 2025-1-8
J Nanobiotechnology. 2024-1-8
Theranostics. 2016-1-1
Proc Natl Acad Sci U S A. 2015-11-10
Nature. 2015-3-19
Nat Rev Immunol. 2014-9-5